entertainment -WSS

entertainment

author：fashion 2025-09-28 04:28:27 Page View：91919

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb will pay $4.1 billion for RayzeBio, the companies said Tuesday, buying into the fast-growing field of using targeted doses of radiation to treat cancer.

RayzeBio, which raised about $350 million in a September initial public offering, is working in radiopharmaceuticals, which pair the tumor-killing power of radiation with the precision of targeted cancer therapies. The company is currently running a pivotal trial of its most advanced drug, RYZ101, in neuroendocrine cancer and has a pipeline of treatments for kidney, liver, and other cancers.

Bristol Myers will pay $62.50 in cash per share of RayzeBio, a roughly 115% premium to the company’s recent trading and more than triple the company’s IPO price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： US Marines prepare to be put on commercial ships to deter Iranian harassment in Strait of Hormuz
Next article： How to save PrEP access — and even expand it

knowledge

Supreme Court strikes down use of affirmative action

ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

Maui funeral service workers on devastation of fires: 'I'm in shock'

1:00InthisimageobtainedfromtheCountyofMauiinHawaii,showsawildfireinLahaina,onAug.9,2023.Hawaiiwildfi

How to save PrEP access — and even expand it

UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

Rivals hope for voter 'fatigue' as Trump's woes mount but base stays loyal: ANALYSIS

9:34FormerPresidentDonaldTrumpspeaksduringarally,July7,2023,inCouncilBluffs,Iowa.CharlieRiedel/AP,FI

entertainment

explore

knowledge

Rivals hope for voter 'fatigue' as Trump's woes mount but base stays loyal: ANALYSIS